Zejing Pharmaceuticals: Zepuping approved for listing

Zejing Pharmaceutical announced that the independently developed hydrochloride of gicasitinib tablets has been approved by the National Medical Products Administration and is suitable for adult patients with intermediate or high-risk primary myelofibrosis and other diseases. This drug is a Class 1 new drug that reduces inflammation and splenomegaly by inhibiting the JAK-STAT signaling pathway. According to Phase III clinical trials, 72.3% of subjects treated for 24 weeks showed a reduction in spleen volume of 35% compared to baseline, demonstrating significant benefits. The hydrochloride of gicasitinib tablets is also included in the 2024 Chinese Society of Clinical Oncology Guidelines for the Diagnosis and Treatment of Malignant Hematologic Diseases, receiving a first-line recommendation for the treatment of myelofibrosis.